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ABSTRACT
Introduction: Osteoporosis is an
under-recognized problem threatening men.
Bisphosphonates are the main treatment but
their comparative efficacy is unclear for men
with osteoporosis. Therefore, we performed this
systematic review with network meta-analyses
to summarize the evidence of comparative
efficacy of bisphosphonates in men with
osteoporosis.
Methods: We completed network
meta-analyses with a frequentist model to
compare the efficacy of different
bisphosphonates. Randomized controlled trials
investigating bisphosphonates used in men
with osteoporosis were included. The primary
outcome was the rate of patients with a new
vertebral fracture. The secondary outcome was
the rate of patients with a non-vertebral
fracture, which was defined as any fractures
reported other than vertebral fractures. Pairwise
meta-analyses were performed to compare
bisphosphonates with placebo. We included
open-label studies in the analyses as a
sensitivity analysis.
Results: Ten trials were included, using
alendronate, ibandronate, risedronate, and
zoledronic acid. No significant difference was
found between any pairs of alendronate,
ibandronate, risedronate, and zoledronic acid
for both vertebral and non-vertebral fractures.
Zoledronic acid ranked as the most effective in
preventing vertebral fracture in primary
osteoporosis. Risedronate ranked best in
preventing non-vertebral fracture in both
primary osteoporosis and
corticosteroid-induced osteoporosis. In the
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sensitivity analyses with the open-label studies,
the ranking order did not change.
Conclusion: The current evidence for
bisphosphonates used in men with
osteoporosis is inadequate. On the basis of the
current evidence, zoledronic acid is most
effective at preventing vertebral fractures,
while risedronate has the highest possibility to
rank the first in preventing non-vertebral
fracture in men with primary osteoporosis and
corticosteroid-induced osteoporosis. More
well-designed studies are needed to test our
findings and to better know the comparative
efficacy of bisphosphonate to prevent vertebral
fracture in men with osteoporosis.
Keywords: Bisphosphonate; Fracture; Men;
Network meta-analysis; Osteoporosis
INTRODUCTION
Osteoporosis is still an under-recognized
problem in men [1]. In a recent updated
systematic review summarizing the evidence of
pharmacologic treatments to prevent fractures
in primary osteoporosis, the author only found
one randomized trial of men with osteoporosis
designed with a primary fracture reduction
outcome [2]. Although the incidence of
osteoporosis in men is less frequent compared
to that in women, a large number of men have
osteoporosis and their health is threatened by
this condition. Approximately 20% of all
clinical vertebral fractures and 30% of all hip
fractures occur in men, but mortality in men
with vertebral or hip fractures is significantly
higher than in women [3–6].
In more than 50% of men with osteoporosis,
the disease is the result of an identifiable cause
that results in bone loss and bone fragility. The
most common causes of secondary osteoporosis
inmen are glucocorticoid excess, hypogonadism,
and excessive alcohol consumption, which are
believed to cause bone resorption to outweigh
bone formation, resulting in bone loss and
fractures in men [3, 7, 8]. Men also suffer bone
loss naturally, which is more common with
deficient testosterone or estradiol level and is
accelerated after the age of 70 years [1].
Three bisphosphonates, namely alendronate,
risedronate, and zoledronic acid, are
recommended for treating men with
osteoporosis in the 2012 clinical practice
guideline of the Endocrine Society [9].
Although bisphosphonates cannot remove the
secondary causes, they may prevent bone loss
and fractures by inhibiting bone resorption [10].
Bisphosphonates have positive effects on bone
mass density and bone biomarkers, and reduce
vertebral fractures inmenwith osteoporosis [11].
In order to clarify the comparative efficacy of
different bisphosphonates in preventing
fractures, several network meta-analyses and
multiple treatment analyses were carried out
[12–14]. However, none of them specifically
addressed men with osteoporosis and these
studies primarily focused on the use of
bisphosphonates in treating postmenopausal
osteoporosis. Therefore, we performed this
systematic review with network meta-analyses
to evaluate the comparative efficacy of
bisphosphonates in men with osteoporosis. We
report the outcomes for osteoporosis with
different causes separately, since patients with




We searched for randomized controlled trials in
the Cochrane Library, Embase, PubMed, and
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ClinicalTrials.gov. Our search terms, combining
osteoporosis and bisphosphonates, consisted of




‘‘risedronate’’, ‘‘tiludronic acid’’, and
‘‘zoledronic acid’’. This search strategy was
amended for each database. We searched each
database from inception until December 27,
2015 (date of final search). We also manually
searched the references of cited articles.
Supplement 1 includes the systematic search
strategy.
Selection Criteria
Studies meeting all the following criteria were
included: (1) randomized controlled trials that
enrolled men with osteoporosis; (2) reported
fracture events; (3) a comparison of
bisphosphonates against other
bisphosphonates or placebo; (4) full-text
publication or clinical trials that reported
results. Trials that enrolled men with
osteoporosis related to cancer were excluded,
as fracture in cancer-associated bone disease
may result from causes other than osteoporosis
[15]. Two independent reviewers (JZ and XZ)
worked together to screen the titles and
abstracts of all initially identified studies
according to the selection criteria.
Outcome Measurement
The primary outcome was new vertebral
fracture. Vertebral fracture outcomes assessed
by quantitative morphometric (QM) or
semiquantitative (SQ) measurements were
collected. For the QM measurents, vertebral
fracture was defined by using ratios derived
from direct vertebral body height
measurements. For the SQ measurements,
vertebral fracture was defined according to
height and area reduction with the help of
visual grading [16]. If both measurements were
used in the assessment of vertebral fracture, we
preferred the data with the higher rate of
reported fractures. The secondary outcome was
non-vertebral fracture. Non-vertebral fracture
included all fractures reported other than
vertebral fracture. Hypogonadism-induced
osteoporosis and primary osteoporosis were
considered the same type of osteoporosis here.
Data Extraction and Quality Assessment
Two reviewers (JZ, XZ) independently extracted
baseline data and assessed the studies’
methodological quality using the risk of
quality assessment tool recommended by the
Cochrane Handbook for randomized controlled
trials [17]. The authors considered random
sequence generation, allocation concealment,
blinding of participants, caregivers, fracture
outcome assessors, incomplete information,
selective reporting, and other bias. The criteria
were all classified into low, high, or unclear risk
of bias on the basis of guidance from The
Cochrane Collaboration [17].
Data Synthesis and Analysis
We excluded comparisons with zero events in
both groups from the relevant analysis since
such comparisons provided no information on
the magnitude of the treatment effect [18].
We conducted network meta-analyses with a
frequentist model [19–21] using STATA release
13.1 [22]. We based direct probability
statements on 50,000-simulation iterations to
identify the best and most representative data,
assuming comparable interstudy variances for
all treatment effects for the same outcomes. The
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assessment of statistical heterogeneity in the
entire network was based on the magnitude of
the heterogeneity variance parameter (s2)
estimated from the network meta-analysis
models [23]. Inconsistency was checked if a
comparison loop existed [24–26]. We included
the randomized but open-label studies in the
network meta-analyses for sensitivity analyses.
We also performed a sensitivity analyses with a
Bayesian model [27] to check on the robustness
of the network meta-analyses.
Pairwise meta-analyses were performed in
Review Manager 5.2 using the random effect
model for each outcome comparing each
bisphosphonate with placebo. For outcomes in
which studies reported zero events in one
treatment arm, we added 0.5 to the numerator
and 1 to the denominator. Results were
expressed as an odds ratio (OR) with 95%
confidence intervals (CI). We assessed and
quantified heterogeneity using Chi2 test and I2
statistic computed in this software.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
After screening 2653 citations and 683 clinical
trials (Fig. 1), we included 10 studies [28–37],
ten of which reported vertebral fractures and
five reported non-vertebral fractures. Patients
who were included were treated with
alendronate, ibandronate, risedronate,
zoledronic acid, or placebo. They were
classified into patients with primary
osteoporosis, corticosteroid-induced
osteoporosis, and osteoporosis with Parkinson
disease. Two studies were head-to-head
comparison trials: One compared zoledronic
acid with risedronate [30] and the other
compared zoledronic acid with alendronate
[36]. Characteristics of the included studies are
summarized in Table 1. Two randomized but
open-label studies [38, 39] were included in the
sensitivity analyses.
Overall, low risk of bias was identified
(Supplement 2). Two studies [34, 35] were at
high risk of bias for incomplete outcome data
because of high rate of loss to follow-up. One
study [35] was at unclear risk of bias in outcome
assessment because of not mentioning the
blinding and another three [28, 29, 35] in
other bias because of the sponsorship by
manufacturers in the studies. Others were at
low risk of bias.
Table 2 summarizes the comparative efficacy
of bisphosphonates versus placebo and the
ranking of different bisphosphonates. Only
one pairwise meta-analysis comparing
risedronate and placebo for
corticosteroid-induced osteoporosis was
performed, since this is the only comparison
including two trials contributing data. Network
meta-analyses were performed for vertebral and
non-vertebral fractures in primary osteoporosis,
and for vertebral fracture in
corticosteroid-induced osteoporosis (Table 3).
Forest plots for network meta-analyses are
provided in Supplements 3 and 4.
Primary Osteoporosis
In the network meta-analyses for vertebral
fracture, no significant difference between any
pairs of bisphosphonates was found.
Compared with placebo, zoledronic acid,
alendronate, and ibandronate prevented
vertebral fracture [OR with 95% CI 0.23
(0.05, 1.06), 0.22 (0.03, 1.55), and 0.26 (0.02,
4.25), respectively], but all with insignificant
difference. Significant heterogeneity was
found in the network meta-analysis
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(s2 = 0.68). One loop existed in the network
meta-analysis for vertebral fracture and no
significant inconsistency was found (P = 0.17).
In the probability ranking order, zoledronic
acid ranked as the most effective agent in
preventing vertebral fracture. On the basis of
one single trial, we found that zoledronic acid
and alendronate prevented vertebral fractures
in primary osteoporosis significantly
[0.32 (0.15, 0.69) and 0.09 (0.01, 0.72),
respectively].
In the network meta-analysis for
non-vertebral fracture, no significant
difference between any pairs of
bisphosphonates was found. Compared with
placebo, zoledronic acid, risedronate, and
alendronate prevented non-vertebral fracture
[0.62 (0.11, 3.37), 0.53 (0.10, 2.99), and 0.78
(0.13, 4.65), respectively], but all with
insignificant difference. Heterogeneity and
inconsistency were not checked, since no
more than two trials for the same comparison
were included and no loop existed. In the
probability ranking order, risedronate ranked
the highest in preventing non-vertebral
fracture.
Potentially relevant references searched via database searching (All 
n=2754; PubMed, n=755; Embase, n=1114; Cochrane, n=785)
Articles retrieved for full text (n=40)
References excluded (n=2714)
 Duplicate (n=1301)
 Not men only (n=667)
 Not osteoporosis (n=37)
 Cancer related osteoporosis (n=111)
 Not bisphosphonates preventing fracture
(n=290)
Included articles and trials (n=11)
Articles excluded (n=30)
 Not men only (n=7)
 Not RCT (n=4)
 No fracture outcome (n=15)




 No results: n=603
Trials excluded (n=149)
 Not men only (n=80)
 Not compare with other 
bisphosphonate (n=44)
 Not RCT (n=3)
 No fracture outcome (n=22)
Included (n=10) Included (n=1)
Trials with results (n=150)
Articles and trials included in network meta-analysis (n=10)
Duplicate: n=1
Fig. 1 Review proﬁle
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Secondary Osteoporosis
For corticosteroid-induced osteoporosis, no
significant difference between any pairs of
bisphosphonates was found for vertebral
fracture in the network meta-analysis.
Compared with placebo, risedronate
significantly prevented vertebral fracture [0.15
(0.04, 0.58)], and zoledronic acid and
alendronate insignificantly prevented vertebral
fracture [0.34 (0.02, 5.34) and 0.60 (0.04, 9.82),
respectively]. No significant heterogeneity was
found (s2 = 0.00). One loop existed in this
network meta-analysis and no significant
inconsistency was found (P = 0.51). In the
probability ranking order, risedronate ranked
the highest in preventing vertebral fracture in
corticosteroid-induced osteoporosis. On the
basis of the meta-analysis, we also found that
risedronate significantly prevented vertebral
fracture in corticosteroid-induced osteoporosis
[0.15 (0.04, 0.57), P = 0.68, I2 = 0].
For osteoporosis with Parkinson disease, only
one trial comparing risedronate with placebo
could be included. It found that risedronate
prevented non-vertebral fracture with
statistically insignificant efficacy [0.32 (0.08,
1.20)].
Table 2 Summary of the outcomes
No. of studies
contributing data
Size Pairwise (OR) Network (OR) Ranking
Primary osteoporosis VF
Zoledronic acid 1 1199 0.32 (0.15, 0.69) 0.23 (0.05, 1.06) 1
Risedronate 1 284 2.47 (0.12, 51.91) 2.47 (0.09, 69.00) 4
Alendronate 1 241 0.09 (0.01, 0.72) 0.22 (0.03, 1.55) 2
Ibandronate 1 133 0.26 (0.02, 3.00) 0.26 (0.02, 4.25) 3
Primary osteoporosis NVF
Zoledronic acid 1 1199 0.65 (0.21, 1.99) 0.62 (0.11, 3.37)a 2
Risedronate 1 284 0.55 (0.18, 1.69) 0.53 (0.10, 2.99)a 1
Alendronate 1 241 0.77 (0.23, 2.60) 0.78 (0.13, 4.65)a 3
Ibandronate 1 133 2.81 (0.13, 59.77) NAb 4
Corticosteriod-induced osteoporosis VF
Zoledronic acid 0 0 NA 0.34 (0.02, 5.34) 2
Risedronate 2 188 0.15 (0.04, 0.57) 0.15 (0.04, 0.58) 1
Alendronate 1 130 0.60 (0.04, 9.82) 0.60 (0.04, 9.82) 3
Osteoporosis with PD NVF
Risedronate 1 242 0.32 (0.08, 1.20) NA NA
VF vertebral fracture, NVF non-vertebral fracture, PD Parkinson disease, NA not available
a Results from ADDIS with Bayesian model because the included studies were not adequate enough to perform the network
meta-analysis using STATA with meta-regression model
b Unstable data with 0 events happen when performing network meta-analysis using Bayesian model
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In the sensitivity analyses including the
open-label studies, results were consistent in
showing that zoledronic acid, risedronate, and
alendronate significantly prevented vertebral
fracture in primary osteoporosis [0.29 (0.15,
0.57), 0.37 (0.20, 0.72), and 0.33 (0.15, 0.70),
respectively] and risedronate significantly
prevented non-vertebral fracture in
corticosteroid-induced osteoporosis [0.50
(0.29, 0.86)]. In the sensitivity analyses using
Bayesian model, we found that alendronate
instead of zoledronic acid ranked best in
preventing vertebral fracture in primary
osteoporosis (Supplement 5).
DISCUSSION
In this systematic review, we summarized the
comparative efficacy of preventing fracture with
bisphosphonates in men with osteoporosis by
integrating all available direct and indirect
evidence. We found that zoledronic acid had
the highest probability to rank best in
preventing vertebral fracture in primary
osteoporosis, and risedronate had the highest
probability to rank best in preventing
non-vertebral fracture in both primary
osteoporosis and corticosteroid-induced
osteoporosis. Our summary of the results also
Table 3 Results of network meta-analyses
Placebo Zoledronic acid Risedronate Alendronate Ibandronate
Vertebral fracture in men with primary osteoporosis
Ibandronate 0.26 (0.02, 4.25) 1.16 (0.05, 27.77) 0.11 (0.00, 8.20) 1.22 (0.04, 36.48) –
Alendronate 0.22 (0.03, 1.55) 0.95 (0.19, 4.68) 0.09 (0.00, 4.21) – –
Risedronate 2.47 (0.09, 69.00) 10.82 (0.28, 424.62) –
Zoledronic acid 0.23 (0.05, 1.06) –
Placebo –
Non-vertebral fracture in men with primary osteoporosisa
Ibandronate NAb NAb NAb NAb –
Alendronate 0.78 (0.13, 4.65) 1.25 (0.12, 14.67) 1.40 (0.13, 15.86) – –
Risedronate 0.53 (0.10, 2.99) 0.85 (0.08, 8.98) –
Zoledronic acid 0.63 (0.11, 3.37) –
Placebo –
Vertebral fracture in men with corticosteroid-induced osteoporosis
Alendronate 0.60 (0.04, 9.82) 1.79 (0.04, 91.17) 4.00 (0.18, 89.08) – –
Risedronate 0.15 (0.04, 0.58)* 0.45 (0.04, 5.00) –
Zoledronic acid 0.34 (0.02, 5.34) –
Placebo –
* Statistically signiﬁcant result
a Results from ADDIS with Bayesian model because the included studies were not adequate enough to perform the network
meta-analysis using STATA with meta-regression model
b Unstable data with 0 events happen when performing network meta-analysis using Bayesian model
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shows that the available eligible studies were
inadequate to have high confidence in results.
More well-designed studies focusing on
bisphosphonates treating men with
osteoporosis are needed.
Studies focused on osteoporosis with
different causes were not combined in the
network meta-analyses to minimize
heterogeneity. Except for evaluating primary
osteoporosis and corticosteroid-induced
osteoporosis, we also found one study showing
that risedronate significantly prevents
non-vertebral fracture in men with
osteoporosis and Parkinson disease [37].
Although cancer-related osteoporosis was not
considered in our analysis, as fracture in
cancer-associated bone disease may result from
causes other than osteoporosis [15], other
meta-analyses [40, 41] found that zoledronic
acid was effective in preventing fractures for
patients under androgen deprivation therapy
for prostate cancer and nonmetastatic prostate
cancer. No other randomized controlled study
investigating the efficacy of bisphosphonates in
men with osteoporosis was found.
Network meta-analyses focusing on the use
of bisphosphonates in treating postmenopausal
women should be considered when treating
men with osteoporosis using bisphosphonates.
Compared with our study, these network
meta-analyses have a larger sample size,
therefore the estimates could be more precise
to show comparative efficacy among different
bisphosphonates. The study by Jansen et al. [13]
found that zoledronic acid and risedronate
ranked the highest in preventing vertebral
fracture and non-vertebral fracture,
respectively, in postmenopausal women,
which is consistent with our systematic review
regarding their efficacy in men. Until adequate
evidence is available to better evaluate
the comparative efficacy of preventing fracture
with bisphosphonates in men, we can also refer
to the available studies for postmenopausal
women.
Our study has a few improvements
compared with the similar network
meta-analysis [42] comparing eight drugs in
treating men with osteoporosis. Different from
the cited analysis, our study exclusively focused
on bisphosphonates, excluding strontium
ranelate, teriparatide, and parathyroid
hormone, which have different mechanisms of
preventing fracture than bisphosphonates. In
addition, our study separated osteoporosis into
primary osteoporosis, corticosteroid-induced
osteoporosis, and osteoporosis with Parkinson
disease. Also, we separated fracture into
vertebral fracture and non-vertebral fracture.
With these approaches, our analysis has lower
heterogeneity and fewer confounding factors.
Limitations exist in this study. Firstly, our
estimates have uncertainty. The evidence for
using bisphosphonates to treat men with
osteoporosis is inadequate, and the sample
sizes of the eligible studies are mostly small.
Secondly, we did not include some studies of
bisphosphonates preventing fracture in men
[43, 44], because women were also included in
these studies and we could not extract the data
of men only. Thirdly, somewhat different
assessment criteria of vertebral fracture were
applied in included studies. Semiquantitative
methods and quantitative morphometric
methods [16] were assumed equally sensitive
in our meta-analysis. Last, heterogeneity from
the study design may exist as only two studies
considered the outcome of fracture as their
primary outcome, while others considered the
outcome of fracture as a secondary outcome.
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CONCLUSION
On the basis of the current evidence, zoledronic
acid is most effective at preventing vertebral
fractures, while risedronate has the highest
possibility to rank the first in preventing
non-vertebral fracture in men with primary
osteoporosis and corticosteroid-induced
osteoporosis. More well-designed studies are
needed to support our findings and to better
know the comparative efficacy of
bisphosphonate to prevent vertebral fracture
in men with osteoporosis.
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